We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
- Authors
Werth, Sebastian; Breslin, Tomás; NiAinle, Fionnuala; Beyer-Westendorf, Jan
- Abstract
Modern direct-acting anticoagulants are rapidly replacing vitamin K antagonists (VKA) in the management of millions of patients worldwide who require anticoagulation. These drugs include agents that inhibit activated factor X (FXa) (such as apixaban and rivaroxaban) or thrombin (such as dabigatran), and are collectively known today as non-VKA oral anticoagulants (NOACs). Since bleeding is the most common and most dangerous side effect of long-term anticoagulation, and because NOACs have very different mechanisms of action and pharmacokinetics compared with VKA, physicians are naturally concerned about the lack of experience regarding frequency, management and outcome of NOAC-associated bleeding in daily care. This review appraises trial and registry (or 'real-world') data pertaining to bleeding complications in patients taking NOACs and VKA and provides practical recommendations for the management of acute bleeding situations.
- Subjects
EDUCATION of physicians; HEMORRHAGE risk factors; ANTICOAGULANTS; BLOOD coagulation factors; DRUG therapy; DRUG interactions; DRUG prescribing; PATIENT education; THROMBIN; VITAMIN K; PHYSICIAN practice patterns; TREATMENT effectiveness; PATIENT selection; DESCRIPTIVE statistics; CHEMICAL inhibitors; PHARMACODYNAMICS
- Publication
American Journal of Cardiovascular Drugs, 2015, Vol 15, Issue 4, p235
- ISSN
1175-3277
- Publication type
Article
- DOI
10.1007/s40256-015-0123-6